SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune responses including hyperinflammation on vital organs, announces the formation of the SeaStar Medical Scientific Advisory Board (SAB).

The SAB is comprised of world-renowned international pediatric and adult clinical experts including nephrologists, critical care intensivists and translational scientists who will advise on the Company’s technology capabilities, share insights on emerging trends in healthcare, and advise on the Company’s critical care and acute kidney injury (AKI) clinical development programs.

“Science and innovation are the foundational pillars of SeaStar Medical and key to our competitive advantage,” said Eric Schlorff, CEO of SeaStar Medical. “We are grateful to be collaborating with this incredible group of top clinical experts and scientists as we continue to develop and commercialize our selective cytopheretic device (SCD). We plan to further broaden our SAB with relevant expertise as we expand beyond our initial AKI clinical programs into other therapeutic categories and indications.”

Members of SeaStar Medical’s SAB include the following:

  • Ayse Akcan-Arikan, MD is the Medical Director of Critical Care Nephrology and Acute Dialysis at Texas Children’s Hospital and Associate Professor of Pediatrics, Baylor College of Medicine
  • David Askenazi, MD, MSPH is the Director of Pediatric and Infant Center for Acute Nephrology (PICAN) at Children’s of Alabama and Professor at the University of Alabama at Birmingham
  • Sean Bagshaw, MD, MSc is the Chair of Critical Care Medicine and Associate Professor of Critical Care Medicine at the University of Alberta
  • Rajit Basu, MD, MS is the Division Head of Critical Care Medicine at the Lurie Children’s Hospital of Chicago and Professor of Pediatrics at Northwestern University Feinberg School of Medicine
  • Andriy Batchinsky, MD is the Founder and Director of the Autonomous Reanimation and Evacuation (AREVA) Program at the Geneva Foundation
  • Sarah Faubel, MD is Professor of Medicine and Nephrologist at the University of Colorado Hospital and Veterans Affairs Medical Center
  • Stuart Goldstein, MD is the Director of the Center for Acute Care Nephrology and Medical Director of Pheresis Service, Co-Director of the Heart Institute Research Core at Cincinnati Children’s Medical Hospital and Professor at the University of Cincinnati’s Department of Pediatrics
  • Marc Jeschke, MD, PhD is the Vice President and Medical Director of Burns and Translational Researcher at Hamilton Health Sciences
  • Jay Koyner, MD is the Medical Director of Acute Dialysis and Director of Nephrology Intensive Care Unit at the University of Chicago Medical Center
  • Kathleen Liu, MD, PhD is a critical care intensivist, and Professor of Medicine and clinical trialist at the University of California at San Francisco School of Medicine
  • Theresa Mottes, MSN, APRN-NP, CPNP-AC, CDN is an Acute Care Nurse Practitioner at the Lurie Children’s Hospital of Chicago

“Several of our SAB members provided key support during discussions with the U.S. Food and Drug Administration (FDA), which resulted in the Approvable Letter for the SCD’s humanitarian device exemption (HDE) in pediatric AKI,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “The advisory board also advised on design elements of our ongoing, pivotal NEUTRALIZE-AKI Phase 3 study with the SCD in adult patients with AKI. We look forward to continued engagement and collaborations with these invaluable experts.”

About SeaStar MedicalSeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or Twitter.

Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to commercialization of SeaStar’s product candidates and contribution from industry experts. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements, including the equity line of credit and forward purchase agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

LHA Investor RelationsJody Cain(310) 691-7100Jcain@lhai.com

# # #

SeaStar Medical (NASDAQ:ICU)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 4월(4) 2024 SeaStar Medical 차트를 더 보려면 여기를 클릭.
SeaStar Medical (NASDAQ:ICU)
과거 데이터 주식 차트
부터 4월(4) 2023 으로 4월(4) 2024 SeaStar Medical 차트를 더 보려면 여기를 클릭.